Comments
Onco Therapies Ltd, the wholly-owned subsidiary of Strides Arcolab, has received its first European Union approval to market chemotherapy drug, Carboplatin, Strides said. Carboplatin injection is given to treat advanced ovarian carcinoma.
It is among 37 drugs licensed to Pfizer on a semi-exclusive basis for sales in 17 European countries. IMS puts its latest European market at $138 million, the release said.
The approval covers select countries.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.